If you haven’t heard of Oncotarget, it is a leading peer-reviewed journal, that is focused on the pathology of all cancers and is predicated on identifying potential treatment, as well as therapy options, that have the potential for improving cancer management, for those struggling with the disease. In addition, the journal focuses on how management programs, therapeutic agents, and other protocols affect patient perspective and quality of life. According to dovepress.com, a publisher of scientific and medical journals, the end-goal of Oncotarget is to “make scientific results rapidly and widely available,” and to achieve this Oncotarget is led by prominent scientists who routinely contribute a wealth of information to the journal.
ONCOTARGET EXPERIENCES SIGNIFICANT GROWTH
Oncotarget is published by Impact Journals, LLC and has been in existence since 2010; Oncotarget has received a favorable impact factor rating (5,6) since the publication began and is taking steps to broaden its appeal amongst readers. In 2015, Oncotarget went from publishing once per month to weekly and the number of papers published also increased; starting in 2010 Oncotarget published 75 papers and then grew to 1,330 by 2014. In 2015 the journal published 3,000 papers, and by 2016 published more than 8,000 papers. One of the things that differentiate Oncotargert from other publications is its caliber of editors and publishers, which are led by Chief Editors Dr. Andrei Gudkov and Mikhail Blagosklonny, both of whom are professors at the Roswell Park Institute.
Oncotarget is recognized as a leading journal when it comes to publishing medical articles; one of the journal’s most notable articles revolved around E-cigarettes. The study, conducted by Dr. IrfanRahman, demonstrated the negative effects of E-liquid (nicotine solution in E-cigarettes) on teeth and gums. Oncotarget strives to publish articles that are thoroughly based in scientific research and provides substantial value to its readers.